The Dermscan Group has reached a new milestone by broadening its range of services and reinforcing its R&D team in partnership with the company TRANSAT which is specialised in the creation of customised functional genomic tools. Created in 2002, TRANSAT creates and produces specific cellular models and bio-molecule banks.
Dermscan reaches further milestone
One of TRANSAT’s outstanding technologies is that relating to RNA Interference or RNAi (posttranscriptional inhibition of target gene expression). This technology has several applications. Cellular models obtained by RNAi enable, in fundamental research, the discovery or validation of activity of a gene and, in development, the screening of the selected molecules and the evaluating of their toxicity.
Within the scope of studies carried out by the Dermscan Group, TRANSAT contributes its know-how in cellular and molecular biology in order to validate the action of pharmacologically active molecules within a specific context: cellulitis, couperosis, pigmentation, ageing, skin sensitivity, etc.
Starting with the cell type best suited for the particular project, TRANSAT modifies the expression of one target gene or several target genes. BIOalternatives studies the action of molecules and then the Dermscan Group clinically evaluates the safety and efficacy of the selected molecule or molecules in humans.
Dermscan Group developed, in 2001, a partnership with the company BIOalternatives for conducting in vitro tests. Since its foundation in 1990, the Dermscan Group has been evaluating in vivo the safety and efficacy of cosmetic and pharmaceutical products.
